MOONLAKE IMMUNOTHERAPEUTICS (MLTX)
KY61559X1045 - Common Stock
Taking everything into account, MLTX scores 3 out of 10 in our fundamental rating. MLTX was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MLTX as it has an excellent financial health rating, but there are worries on the profitability. MLTX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year MLTX has reported negative net income.
In the past year MLTX has reported a negative cash flow from operations.
MLTX had negative earnings in each of the past 5 years.
MLTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MLTX has a better Return On Assets (-15.59%) than 81.77% of its industry peers.
MLTX has a better Return On Equity (-16.54%) than 87.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.59% | ||
| ROE | -16.54% | ||
| ROIC | N/A |
ROA(3y)-208.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for MLTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, MLTX has more shares outstanding
There is no outstanding debt for MLTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 66.21 indicates that MLTX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 66.21, MLTX belongs to the best of the industry, outperforming 99.11% of the companies in the same industry.
There is no outstanding debt for MLTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 66.21 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
MLTX has a Current Ratio of 25.51. This indicates that MLTX is financially healthy and has no problem in meeting its short term obligations.
MLTX's Current ratio of 25.51 is amongst the best of the industry. MLTX outperforms 96.99% of its industry peers.
A Quick Ratio of 25.51 indicates that MLTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 25.51, MLTX belongs to the best of the industry, outperforming 96.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 25.51 | ||
| Quick Ratio | 25.51 |
3. Growth
3.1 Past
The earnings per share for MLTX have decreased strongly by -35.79% in the last year.
EPS 1Y (TTM)-35.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
MLTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.07% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-138.26%
EPS Next 2Y-89.45%
EPS Next 3Y-64.65%
EPS Next 5Y13.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MLTX. In the last year negative earnings were reported.
Also next year MLTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MLTX's earnings are expected to decrease with -64.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-89.45%
EPS Next 3Y-64.65%
5. Dividend
5.1 Amount
MLTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ:MLTX (12/20/2024, 8:24:51 PM)
After market: 52.17 0 (0%)52.17
+0.29 (+0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.39%
Inst Owner Change2.61%
Ins Owners12.86%
Ins Owner Change-26.41%
Market Cap3.33B
Analysts84.35
Price Target75.4 (44.53%)
Short Float %14.91%
Short Ratio34.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.01%
Min EPS beat(2)-37.92%
Max EPS beat(2)-26.1%
EPS beat(4)1
Avg EPS beat(4)-6.67%
Min EPS beat(4)-37.92%
Max EPS beat(4)48.88%
EPS beat(8)5
Avg EPS beat(8)5.68%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.46%
PT rev (3m)1.45%
EPS NQ rev (1m)-17.77%
EPS NQ rev (3m)-46.97%
EPS NY rev (1m)-12.17%
EPS NY rev (3m)-13.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.83 | ||
| P/tB | 6.83 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.29
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.26
OCFYN/A
SpS0
BVpS7.64
TBVpS7.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.59% | ||
| ROE | -16.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-208.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 25.51 | ||
| Quick Ratio | 25.51 | ||
| Altman-Z | 66.21 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.11%
EPS Next Y-138.26%
EPS Next 2Y-89.45%
EPS Next 3Y-64.65%
EPS Next 5Y13.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-94.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-147.71%
EBIT Next 3Y-69.76%
EBIT Next 5YN/A
FCF growth 1Y-56.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.45%
OCF growth 3YN/A
OCF growth 5YN/A